![Abbott raises 2022 profit forecast after strong COVID-19 test demand](https://sureanot.com/wp-content/uploads/2022/07/abbott-raises-2022-profit-forecast-after-strong-covid-19-test-demand.jpg)
![](https://onecms-res.cloudinary.com/image/upload/s--q-nU-Pt2--/fl_relative,g_south_east,l_one-cms:core:watermark:reuters,w_0.1/f_auto,q_auto/c_fill,g_auto,h_676,w_1200/v1/one-cms/core/2022-07-20t113439z_1_lynxmpei6j0jh_rtroptp_3_abbott-baby-formula.jpg?itok=K3wDEDnV)
Abbott Laboratories on Wednesday (Jul 20) raised its annual earnings forecast as demand for its medical devices and diagnostics products helped cushion the impact of a shutdown of its baby formula plant.
COVID-19 testing has shielded the company’s earnings during the pandemic when demand for its medical devices was hurt by deferred elective procedures.
The company reported COVID-19 testing-related sales of US$2.3 billion in the second quarter, while medical device sales rose 2.5 per cent in the quarter.
Abbott said it expects at least US$4.90 per share in adjusted earnings in 2022, compared with at least US$4.70 forecast earlier.
Sales at Abbott’s nutrition unit fell 7.4 per cent, hit by a recall of its baby formulas and a months-long shutdown at its Michigan plant, which has been at the center of a baby formula shortage in the United States.